Search
Prothena Corporation PLC
PRTAAdd to Watchlist
8.120USD
-0.290-3.45%
Close 07-31 16:00（ET）Quotes delayed by 15 min
425.11MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Prothena Corporation PLC is 6.67, ranking 325 out of 385 in the Biotechnology & Medical Research industry. The average price target is 18.50, with a high of 36.00 and a low of 8.00.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
21.400
Target Price
+163.55%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Prothena Corporation PLC
PRTA
6
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Prothena Corporation PLC's expected revenue for the next quarter?
Prothena Corporation PLC's expected revenue is 28.30M.
What is Prothena Corporation PLC's price target?
Analysts forecast that Prothena Corporation PLC's price target is USD 18.50, with the highest forecast at USD 36.00 and the lowest forecast at USD 8.00.
How have Prothena Corporation PLCPRTA's recent earnings per share performed?
The market expectation was USD 0.61, while Prothena Corporation PLCPRTA's earnings per share (EPS) for the previous quarter was USD -0.40. EPS for the next quarter is expected at USD -0.39.
What is the analyst rating for Prothena Corporation PLC?
Based on the ratings of Prothena Corporation PLC's stock from 6 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.